Ark Biosciences to Present Efficacy Data on Novel Ziresovir at an International Conference
Ark Biosciences (Ark) to present efficacy data on its novel RSV F-protein inhibitor, Ziresovir (AK0529) at the 11th International RSV Symposium in Asheville, North Carolina, USA, 31st October – 4th November 2018
Ark has submitted an abstract reporting single dose clinical efficacy of its novel RSV F-protein inhibitor Ziresovir, formerly known as AK0529, in infants hospitalized for lower respiratory tract infection with naturally acquired RSV infection. The data to be presented is from the Phase II ‘VICTOR (Viral Inhibition in Children for Treatment of RSV)’ study, “A Randomised, Double-blind, Placebo-controlled, 2-Part Study of Orally Administered AK0529 to Evaluate the Safety, Tolerability, Pharmacokinetics and Antiviral Effect of Single and Multiple Dosing in Hospitalised Infants with Respiratory Syncytial Virus Infection”.
Popular recommendations
-
ArkBio Publishes the Molecular Mechanism of Ziresovir for Treatment of RSV in “PLOS Pathogens”2026-03-23
-
Novel Anti-Fibrotic Drug AK3280 Cleared by FDA to Initiate Phase 2 Proof-of-Concept Clinical Trial in IPF2026-02-12
-
ArkBio Receives China Marketing Authorization for Aizhida for the Treatment of ADHD2026-01-06
-
ArkBio Initiates Phase II Clinical Trial of AK0610, a Preventive Monoclonal Antibody for Respiratory Syncytial Virus Infection2025-10-30
-
ArkBio' Ziresovir Included into Pediatric RSV Drug Priority List by WHO2025-07-16
-
ArkBio's New Drug Application for ADHD Therapeutic AK0901 Accepted and Granted Priority Review by China NMPA2025-06-16
-
ArkBio and Partex Deepen Strategic Collaboration to Advance Novel ATR Inhibitor AK0658 Through AI-Driven Global Development2025-05-30
-
ArkBio Announces Positive Phase II Results of AK3280 for Treatment of Idiopathic Pulmonary Fibrosis (IPF)2025-05-16
-
The Lancet Child & Adolescent Health Publishes Phase III Trial and 24-Month Follow-Up Results of Ziresovir for RSV in Infants Under 6 Months2025-04-16
